The pediatric oncology program at NewYork-Presbyterian/Columbia is one of the front-runners nationally instituting and implementing real-time precision oncology for patients, including the establishment in 2014 of a precision-in-pediatric sequencing program called the PIPseq Cancer Program.

Chimeric antigen receptor (CAR) T-cell therapy engages an individual’s own immune cells to treat cancer, and, in particular, hematological malignancies.

See what our specialists say about gene therapy's role in the treatment of thalassemia and hemophilia.